Sarepta Therapeutics, Inc. (SRPT) stock prices updated...
 

Sarepta Therapeutics, Inc. stock price

Sarepta Therapeutics, Inc. latest news:


  • 11/10/2017 01:27:07

    BRIEF-Sarepta Therapeutics says exercise of option to purchase additional convertible senior notes due 2024

    * SAREPTA THERAPEUTICS ANNOUNCES EXERCISE OF INITIAL PURCHASERS’ OPTION TO PURCHASE ADDITIONAL CONVERTIBLE SENIOR NOTES DUE 2024 Source text for Eikon: Further company coverage:

  • 11/07/2017 14:47:01

    BRIEF-Sarepta Therapeutics announces proposed offering of $375 mln of convertible senior notes

    Sarepta Therapeutics Inc(SRPT). * Sarepta Therapeutics(SRPT) announces proposed offering of $375 million of convertible senior notes due 2024.

  • 09/29/2017 09:36:50

    Sarepta Therapeutics shares dive on safety issues in FDA database

    Sarepta Therapeutics Inc. shares declined as much as 8% in morning trade Friday on safety issues reported in the Food and Drug Administration's Adverse Events Reporting System (FAERS) for the company's controversial Exondys 51 therapy. The FAERS database showed 13 serious events connected to the Duchenne muscular dystrophy therapy, including three patient deaths. But "we believe these reported issues are generally expected outcomes of a progressive fatal disease like DMD and are not necessarily due to any mechanistic or safety flaws of the drug itself," said Leerink Partners analyst Joseph Schwartz. Company management told Leerink that the reported deaths happened in patients late in the disease, towards the end of their lives, according to Schwartz. FAERS, which the FDA recently made more accessible and user-friendly, "while insightful, requires a bit more diligence for full interpretation," Schwartz said. Sarepta did not immediately return MarketWatch's request for comment. Shares were most recently down 2.9%. Shares have surged 37.2% over the last three months, compared with a 4% rise in the S&P 500 .Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 09/28/2017 17:13:44

    PTC Therapeutics gains after FDA panel votes against drug approval

    PTC Therapeutics Inc. stock gained 10% in after-hours action Thursday after trading was halted for the entire regular session as a Food and Drug Administration panel discussed the company's Duchenne muscular dystrophy drug. The panel eventually voted not to approve the drug, saying that more testing was required to prove its efficacy, though they did not completely reject the drug. The FDA does not have to follow the panel's recommendation, as it showed in controversially approving a drug for the same disease last year from Sarepta Therapeutics Inc. despite a panel recommendation against the approval. After being halted at Wednesday's closing price of $17.46 all day, PTC shares resumed trading just before 6 p.m. Eastern time Thursday and topped $19.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • More trends:

    SB Financial Group, Inc.SBFG | SB Financial Group, Inc.SBFGP | SBA Communications CorporationSBAC | ScanSource, Inc.SCSC | Schmitt Industries, Inc.SMIT | Schnitzer Steel Industries, Inc.SCHN | Scholastic CorporationSCHL | SciClone Pharmaceuticals, Inc.SCLN | Scientific Games CorpSGMS | SciQuest, Inc.SQI |